2,2'-Hydroxyethylaminopyrazin | 1640-86-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,2'-Hydroxyethylaminopyrazin
• 英文别名: 2-pyrazin-2-ylamino-ethanol；2-[(Pyrazin-2-yl)amino]ethan-1-ol；2-(pyrazin-2-ylamino)ethanol
• CAS: 1640-86-4
• 化学式: C₆H₉N₃O
• mdl: MFCD11124105
• 分子量: 139.157
• InChiKey: SMHOMFGFMJZEMW-UHFFFAOYSA-N

物化性质

• 沸点：
  324.1±27.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  58
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,2'-Hydroxyethylaminopyrazin 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二甲基亚砜 为溶剂， 生成 2-(3,5-dibromopyrazin-2-ylamino)ethanol
  参考文献：
  名称：

  2,3-Diaminopyrazines as rho kinase inhibitors

  摘要：

  Inhibition of rho kinase ( ROCK) has been recognized as an important target for a number of diseases, including glaucoma. Herein we report SAR development around two hits from a kinase library that led to the discovery of the ROCK inhibitor compound 38. In vitro and in vivo analysis of this compound, including its effects in a monkey model of glaucoma will be discussed. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.012
• 作为产物：
  描述：

  2-氯吡嗪 、 C.I.酸性橙108 以 methanol-dichloromethane 为溶剂， 以to give the title compound (1.21 g, 8.70 mmol, yield: 99%) of yellow liquid form的产率得到2,2'-Hydroxyethylaminopyrazin
  参考文献：
  名称：

  FUSED HETEROCYCLIC COMPOUND

  摘要：

  本发明涉及一种具有式1的融合杂环化合物，其作为血小板聚集抑制剂有用，一种制备该化合物的方法，以及包含该化合物的抑制血小板聚集的药物组合物。

  公开号：

  US20110166121A1

文献信息

• FUSED HETEROCYCLIC COMPOUND
  申请人：Lee Chang Seok

  公开号：US20110166121A1

  公开（公告）日：2011-07-07

  The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.

  本发明涉及具有化学式1的融合杂环化合物，其作为血小板聚集抑制剂有用，以及制备该化合物的方法，以及包含该化合物的用于抑制血小板聚集的药物组合物。
• Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
  申请人：Hellberg R. Mark

  公开号：US20060142307A1

  公开（公告）日：2006-06-29

  Methods for using aminopyrazine analogs to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of aminopyrazine analogs, are also disclosed.

  使用氨基吡唑类似物治疗rho激酶介导的疾病或rho激酶介导的状况的方法被披露。这些疾病或状况包括控制眼内压和治疗青光眼。还披露了用于治疗眼疾如青光眼以及用于控制眼内压的眼科药物组合物，该组合物包含有效量的氨基吡唑类似物。
• AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS
  申请人：Hellberg Mark

  公开号：US20080269249A2

  公开（公告）日：2008-10-30

  Methods for using aminopyrazine analogs to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of aminopyrazine analogs, are also disclosed.

  本发明公开了使用氨基吡嗪类似物治疗rho激酶介导的疾病或rho激酶介导的状况的方法，包括控制眼压和治疗青光眼。本发明还公开了用于治疗眼部疾病（如青光眼）和控制眼压的眼科药物组合物，该组合物包括有效量的氨基吡嗪类似物。
• AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES
  申请人：ALCON INC.

  公开号：EP1830853A2

  公开（公告）日：2007-09-12
• CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE
  申请人：BASF SE

  公开号：EP2367794B1

  公开（公告）日：2013-01-09